Company overview
Provectus Algae develops scalable biomanufacturing platforms using photosynthetic microalgae and Precision Photosynthesis technology to produce high-value compounds for pharmaceuticals, nutraceuticals, and therapeutics. Their closed-system bioreactors enable controlled production of target substances like peptides, proteins, and bioactive ingredients for drug development and synthetic biology applications. The company supports R&D in sustainable bioproducts across food, cosmetics, agriculture, and pharma sectors.
Provectus Algae is listed in the NovaPharmaNews Supplier Hub as a CRO & Clinical Services, CDMO & Manufacturing partner serving United States & Americas. Core focus areas include algae biomanufacturing, microalgae pharma, precision photosynthesis, synthetic biology algae, therapeutic algae compounds.
Industry categories: CRO & Clinical Services, CDMO & Manufacturing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.provectusalgae.com
- Categories
- CRO & Clinical Services, CDMO & Manufacturing
- Markets served
- United States & Americas
- Keywords
- algae biomanufacturing, microalgae pharma, precision photosynthesis, synthetic biology algae, therapeutic algae compounds
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What biomanufacturing capabilities does Provectus Algae offer for pharma R&D?
- Provectus Algae provides modular, automated bioreactors with Precision Photosynthesis and AI-enabled systems to produce high-value microalgae compounds, including peptides and proteins via chloroplast expression for therapeutics and synthetic biology.
- What industries and applications do they serve?
- They target pharmaceuticals, nutraceuticals, cosmetics, food & beverage, agriculture, and therapeutics with sustainable algae-derived ingredients like bioactive compounds, UV-blockers, antioxidants, and feed supplements.
- What is their production scale and geographic focus?
- Operating from Australia with capacities scaling from 110,000 to 260,000 liters, their modular systems can deploy globally; they plan US expansion and emphasize contamination-controlled, closed-loop production.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
